A Methyl-Substituted Spiro-Hydroquinone Exerts Antiplatelet Activity by Blocking Mitochondrial Function In Vitro

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Biochemistry

Background:

• Antiplatelet therapy aims to prevent thrombosis without causing bleeding.
• Current treatments face challenges with resistance and recurrent thrombotic events.
• Novel antiplatelet agents with improved safety profiles are needed.

Purpose of the Study:

• To synthesize and characterize novel spiro-hydroquinone derivatives as potential antiplatelet agents.
• To investigate the structure-activity relationship of these derivatives based on aliphatic chain length.
• To evaluate the antiplatelet efficacy and safety of the lead compound, SD3A.

Main Methods:

• Synthesis and characterization of spiro-hydroquinone derivatives with varying aliphatic chain lengths (1-9 carbons).
• Assessment of antiplatelet activity, focusing on collagen-mediated platelet activation.
• Evaluation of cytotoxicity and solubility of the synthesized compounds.
• In vitro assessment of thrombus formation and coagulation effects.

Main Results:

• Increasing aliphatic chain length did not improve antiplatelet activity and increased cytotoxicity and reduced solubility.
• The shortest derivative, SD3A, demonstrated potent antiplatelet activity by inhibiting mitochondrial function.
• SD3A selectively inhibited collagen-mediated platelet activation, reducing thrombus formation.
• SD3A showed low cytotoxicity and did not affect coagulation in vitro, indicating a low bleeding risk.

Conclusions:

• ortho-carbonylhydroquinone spiro derivatives, particularly SD3A, show promise as antiplatelet agents.
• SD3A exhibits selective antiplatelet activity against collagen with an favorable safety profile.
• SD3A represents a potential therapeutic candidate for preventing thrombotic events with reduced bleeding risk.